Fisher & Paykel Healthcare Corporation Limited ( (FSPKF) ) has released its Q2 earnings. Here is a breakdown of the information Fisher & Paykel Healthcare Corporation Limited presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Fisher & Paykel Healthcare Corporation Limited is a New Zealand-based company specializing in the design, manufacture, and marketing of medical device products and systems for use in hospital and homecare settings, with a focus on respiratory care and sleep apnea treatment.
The company reported strong financial results for the first half of the 2026 fiscal year, achieving over $1 billion in revenue for the first time in this period. Key highlights include a 14% increase in operating revenue to $1.09 billion and a 39% rise in net profit after tax to $213 million.
Fisher & Paykel Healthcare’s hospital product group saw a 17% revenue increase to $692.2 million, driven by a shift in clinical practices and strong demand across its portfolio. The homecare product group also performed well, with a 10% revenue increase to $395.9 million. The company has been recognized with industry awards and is expanding its product offerings and infrastructure, including the construction of a new building at its East Tāmaki campus.
Looking ahead, Fisher & Paykel Healthcare remains focused on leveraging its expertise to drive changes in clinical practices and expand its market presence. The company is committed to ongoing investment in research and development to support its growth strategy.